We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacotherapy and Intensive Treatment of Drug Abuse - 1

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000217
First Posted: September 21, 1999
Last Update Posted: April 16, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Institute on Drug Abuse (NIDA)
VA Office of Research and Development
Information provided by (Responsible Party):
University of Kansas Medical Center ( University of Kansas )
  Purpose
The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.

Condition Intervention Phase
Cocaine-Related Disorders Substance-Related Disorders Drug: Carbamazepine Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacotherapy and Intensive Treatment of Drug Abuse

Resource links provided by NLM:


Further study details as provided by University of Kansas Medical Center ( University of Kansas ):

Primary Outcome Measures:
  • Drug use
  • Effectiveness of medication
  • Level of pharm
  • Retention
  • Depression, anxiety

Study Start Date: September 1990
Primary Completion Date: October 1996 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000217


Locations
United States, Missouri
University of Kansas
Kansas City, Missouri, United States, 64128
Sponsors and Collaborators
University of Kansas
National Institute on Drug Abuse (NIDA)
VA Office of Research and Development
Investigators
Principal Investigator: William Haning, M.D. University of Kansas
  More Information

Publications:
J Addictive Dis. 13; 1994

Responsible Party: University of Kansas
ClinicalTrials.gov Identifier: NCT00000217     History of Changes
Other Study ID Numbers: NIDA-06954-1
R18DA006954 ( U.S. NIH Grant/Contract )
R18-06954-1
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: April 16, 2015
Last Verified: April 2015

Keywords provided by University of Kansas Medical Center ( University of Kansas ):
drug abuse

Additional relevant MeSH terms:
Disease
Substance-Related Disorders
Cocaine-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Carbamazepine
Anticonvulsants
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers
Molecular Mechanisms of Pharmacological Action